Table 25Median treatment ranks and probability of being the best treatment for all interventions for mean blood loss, vaginal birth subgroup

InterventionMedian (95% CrI) treatment rankProbability of being best
Carbetocin2 (1, 5)39.21%
Carboprost2 (1, 7)23.97%
Misoprostol plus oxytocin5 (1, 11)4.72%
Ergometrine plus oxytocin6 (2, 11)0.20%
Misoprostol >600 mcg and ≤ 800 mcg6 (2, 12)1.88%
Oxytocin >5 IU and ≤ 10 IU7 (4, 10)0.00%
Misoprostol >800 mcg and ≤ 1000 mcg7 (1, 13)7.59%
Oxytocin ≤1 IU8 (1, 13)22.00%
Oxytocin >1 IU and ≤ 5 IU8 (3, 12)0.22%
Misoprostol ≤ 600 mcg8 (5, 11)0.00%
Ergometrine9 (5, 12)0.00%
Oxytocin > 10 IU11 (4, 13)0.22%
Placebo12 (10, 13)0.00%

From: Evidence reviews for uterotonics for the prevention of postpartum haemorrhage

Cover of Evidence reviews for uterotonics for the prevention of postpartum haemorrhage
Evidence reviews for uterotonics for the prevention of postpartum haemorrhage: Intrapartum care: Evidence review M.
NICE Guideline, No. 235.
Copyright © NICE 2023.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.